Evidence map›Paper›PMID 31775744›Full record

ReviewHarm reduction journal2019

Snus: a compelling harm reduction alternative to cigarettes.

Elizabeth Clarke, Keith Thompson, Sarah Weaver, Joseph Thompson, Grant O'Connell

Abstract readComparative StudyReview
In one paragraph

Review in Harm reduction journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Interventions for smokeless tobacco use cessation.The Cochrane database of systematic reviews · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elizabeth ClarkeImperial Brands Plc, 121 Winterstoke Road, Bristol, BS3 2LL, UK. Elizabeth.Clarke@uk.imptob.com.ORCID 0000-0003-2193-4059
Keith ThompsonElucid8 Holdings Ltd, Ballymena Business Centre, 62 Fenaghy Road, Ballymena, BT42 1FL, UK.
Sarah WeaverImperial Brands Plc, 121 Winterstoke Road, Bristol, BS3 2LL, UK.
Joseph ThompsonImperial Brands Plc, 121 Winterstoke Road, Bristol, BS3 2LL, UK.
Grant O'ConnellImperial Brands Plc, 121 Winterstoke Road, Bristol, BS3 2LL, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namely lung cancer, cardiovascular disease, pancreatic cancer, diabetes, oral cancer and non-neoplastic oral disease. The review also examines the harm reduction potential of snus as an alternative to cigarettes by comparing the prevalence of snus use and cigarette smoking, and the reported incidence of tobacco-related diseases across European Union countries. The scientific literature generally indicates that the use of snus is not a significant risk factor for developing lung cancer, cardiovascular disease, pancreatic cancer or oral cancer. Studies investigating snus use and diabetes have reported that high consumption of snus (estimated as being four or more cans per week) may be associated with a higher risk of developing diabetes or components of metabolic syndrome; however, overall results are not conclusive. Snus use is associated with the presence of non-neoplastic oral mucosal lesions which are reported to heal rapidly once use has stopped. The most recent Eurobarometer data from 2017 reported that Sweden had the lowest prevalence of daily cigarette use in the European Union at 5% whilst daily "oral tobacco" use was reported to be 20%. European data published by the World Health Organisation in 2018 indicated that Sweden had the lowest rate of tobacco-related mortality and the lowest incidence of male lung cancer. Overall, prevalence statistics and epidemiological data indicate that the use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden when compared with the rest of Europe. The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking.

Indexed as

Harm ReductionTobacco, SmokelessCause of DeathCross-Cultural ComparisonEuropeHumansMyocardial InfarctionOdds RatioPublic HealthSmokingSmoking CessationCigarette smokingEpidemiologyHarm reductionHealth effectsPublic healthSnusTobacco

Identifiers

PMID31775744
PMCPMC6882181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.